Navigation Links
Wake Pharm US Announces Appointment of Jeffrey A. Niezgoda, M.D. to the Board of Medical Advisors
Date:6/28/2009

ELK GROVE VILLAGE, Ill., June 29 /PRNewswire/ -- Wake Pharm US announced today the appointment of Jeffrey A. Niezgoda, MD, FACHM, FACEP, FAPWCA as Director of the Company's Medical Advisory Board.

Dr. Jeffrey Niezgoda is a leading wound management physician and the Medical Director of the Centers for Comprehensive Wound Care and Hyperbaric Oxygen Therapy in Milwaukee, Wisconsin. He also serves as the President and Chief Operating Officer of Hyperbaric & Wound Care Associates, a medical specialty group serving Southeastern Wisconsin and Northern Illinois, and as the President of the American College of Hyperbaric Medicine.

Dr. Niezgoda stated, "I am very pleased to accept the position of Director of the Advisory Board and to have the opportunity to contribute to the company's clinical mission. My clinical experience with Wound Be Gone(R) has produced impressive results with improved wound healing trajectories. Wound Be Gone(R) is placing wound care into the hands of people who might otherwise suffer or whose wound problems might escalate to need for expensive invasive medical intervention."

Ludek Lolek, President & CEO of Wake Pharm US commented, "Dr. Niezgoda has been an invaluable resource to the Wound Be Gone(R) brand. His clinical insight and experience has been a tremendous asset to our development team. As Director of our Medical Advisory Board, Dr. Niezgoda will help us to accelerate the growth of our product line."

Wound-Be-Gone(R) is a novel hydrophilic gel that has been shown to demonstrate enhanced wound healing in varied clinical settings with both acute and chronic wounds. The mechanism of action appears to be related to a decrease in inflammatory mediators due to the active scavenging of oxygen free radicals. Visit www.woundbegone.com for more details.

About Wake Pharm US:

Wake Pharm US is an innovative and international company with its own manufacturing facility located in the Czech Republic (European Union). Wake Pharm US specializes in developing, marketing and distribution of revolutionary and unique products to the health marketplace. For further information about Wake Pharm US, please visit our website at www.wakepharmus.com.


'/>"/>
SOURCE Wake Pharm US
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Updates on Financial Position
2. WuXi PharmaTech Files 2008 Annual Report on Form 20-F
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Action
4. Pharmacomechanical Thrombectomy Procedure Adoption to Accelerate Due to More Aggressive Treatment of Deep Vein Thrombosis, According to Millennium Research Group
5. Labopharm amends debt facility agreement with Hercules
6. Watson Pharmaceuticals Receives FDA Approval For Generic PLAN B(R)
7. The Crohns & Colitis Foundation and Procter & Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners
8. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Vascular Imaging Applications of Its PS-Targeting Platform
9. DiaGenic to Provide MCI Biomarkers for Merz Pharmaceuticals
10. CNI Pharmacy Technician Program
11. RetireSafe Salutes Pharmaceutical Research and Manufacturers of America for Its Commitment to Cut Drug Prices and Help Seniors in the Medicare Doughnut-Hole
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma Research Foundation ... research and serving the lymphoma community through a comprehensive series of education programs, ... Event in New York City, with long-time partners The Paul Foundation, on November ...
(Date:12/4/2016)... Aliso Viejo, California (PRWEB) , ... December 04, ... ... self-animating lower third presets that have new attractive animation styles with unique displacement ... Pro3rd Displace features 30 pre-animated lower third designs. Choose from a variety of ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Lori G. ... Traurig, LLP’s Atlanta office, will speak at the American Conference Institute’s 21st Drug ... Traurig is also a Lead Sponsor of the conference. , Cohen, who chairs the ...
(Date:12/2/2016)... ... December 02, 2016 , ... Advanced Inc., a leading provider of ... Bice, CPA, MBA to serve as Advanced Inc.’s Chief Financial Officer, effective December 1, ... Jason brings extensive financial and operational leadership experience to Advanced Inc. He began his ...
(Date:12/2/2016)... PA (PRWEB) , ... December 02, 2016 , ... With ... struggling through rehabilitation of an injury, patients must find the one that works for ... his pain, he created a machine that worked and decided to share it with ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)...   Pairnomix, LLC, a genetic research company and ... the White House, today announced that findings from its first ... candidate therapies for a patient with epileptic encephalopathy caused by ... at the 70 th Annual Meeting of the ... , December 2-6, 2016.  Pairnomix, unique process involves ...
(Date:12/4/2016)... EAST HANOVER, N.J. , Dec. 3, 2016 /PRNewswire/ ... SEG101 (crizanlizumab, formerly SelG1), an anti-P-selectin antibody, reduced the ... by 45.3% compared to placebo (1.63 vs 2.98, p=0.010) ... Novartis today announced that the data are being featured ... American Society of Hematology (ASH) Annual Meeting and ...
(Date:12/4/2016)... Dec. 3, 2016  Findings from a Novartis ... CTL019, an investigational chimeric antigen receptor T cell ... young adult patients with B-cell acute lymphoblastic leukemia ... session at the 58th American Society of Hematology ... p.m.). The global Phase II study found that ...
Breaking Medicine Technology: